Rabies virus glycoprotein serology ELISA for measurement of neutralizing antibodies in sera of vaccinated human subjects

Highlights•First serology ELISA based on recombinant RABV GP for measurement of virus neutralizing antibodies. •Manufacturing and assay protocol are well-standardized with reliable production and test data. •The specificity and sensitivity of ELISA are 100% and 91.1% when benchmarked with the RFFIT...

Full description

Saved in:
Bibliographic Details
Published inVaccine Vol. 37; no. 41; pp. 6060 - 6067
Main Authors Zhao, Rongqing, Yu, Pengcheng, Shan, Yi, Thirumeni, Nagarajan, Li, Maohua, Lv, Yanli, Li, Jianli, Ren, Wenlin, Huang, Lisong, Wei, Jingshuang, Sun, Yufei, Zhu, Wuyang, Sun, Le
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier Ltd 24.09.2019
Elsevier Limited
Subjects
Allergy and Immunology
Antibiotics
Antibodies
Antigens
Assaying
Diagnostic systems
Dilution
ELISA
Enzyme-linked immunosorbent assay
Glycoprotein (GP)
Glycoproteins
Human subjects
Immune response
Immune system
Immunity
Immunoglobulins
Lyssavirus
Mammalian cells
Medical research
Protective coatings
Rabies
Rabies Virus (RABV)
Reproducibility
Sensitivity
Sensitivity analysis
Serology
Standardization
Technicians
Vaccination
Vaccines
Virus neutralizing antibody (VNA)
Viruses
United States > US
China
Virus neutralizing antibody (VNA)
Rabies Virus (RABV)
Glycoprotein (GP)
ELISA
Online AccessGet full text

Cover

More Information
Summary:Highlights•First serology ELISA based on recombinant RABV GP for measurement of virus neutralizing antibodies. •Manufacturing and assay protocol are well-standardized with reliable production and test data. •The specificity and sensitivity of ELISA are 100% and 91.1% when benchmarked with the RFFIT method. •The ELISA offers a simple, cost-effective and rapid tool to assess the effectiveness of vaccination.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2019.08.043